{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T21:02:07Z","timestamp":1780002127861,"version":"3.53.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jid.2026.01.016","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:03:56Z","timestamp":1770077036000},"page":"1684-1687.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Baricitinib in the treatment of adults with pyoderma gangrenosum: An open-label pilot trial"],"prefix":"10.1016","volume":"146","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6552-5605","authenticated-orcid":false,"given":"Morgan","family":"Vague","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4739-9974","authenticated-orcid":false,"given":"Sharon I.","family":"Choe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6986-9607","authenticated-orcid":false,"given":"Shannon K.","family":"Throckmorton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-0436-6966","authenticated-orcid":false,"given":"Alexandra","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5028-9269","authenticated-orcid":false,"given":"Alex G.","family":"Ortega-Loayza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2026.01.016_bib1","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000365390","article-title":"Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data","volume":"230","author":"Basra","year":"2015","journal-title":"Dermatology"},{"key":"10.1016\/j.jid.2026.01.016_bib11","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.jid.2024.09.023","article-title":"Insights into the pathogenesis of pyoderma gangrenosum","volume":"145","author":"Becker","year":"2025","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.01.016_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1136\/ard-2023-223850","article-title":"Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story","volume":"83","author":"Bonelli","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jid.2026.01.016_bib4","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/ijd.16676","article-title":"JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum","volume":"62","author":"Castro","year":"2023","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jid.2026.01.016_bib5","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1001\/jamadermatol.2023.3115","article-title":"Pain as a patient-reported outcome measure in pyoderma gangrenosum","volume":"159","author":"Erickson","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jid.2026.01.016_bib6","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3389\/fimmu.2018.01510","article-title":"Janus kinase inhibitor baricitinib modulates human innate and adaptive immune system","volume":"9","author":"Kubo","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2026.01.016_bib7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s40257-022-00699-8","article-title":"Pyoderma gangrenosum: an updated literature review on established and emerging pharmacological treatments","volume":"23","author":"Maronese","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jid.2026.01.016_bib8","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.jid.2021.08.431","article-title":"Molecular and cellular characterization of pyoderma gangrenosum: implications for the use of gene expression","volume":"142","author":"Ortega-Loayza","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jid.2026.01.016_bib9","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s12325-023-02445-w","article-title":"Baricitinib safety for events of special interest in populations at risk: analysis from randomised trial data across rheumatologic and dermatologic indications","volume":"40","author":"Taylor","year":"2023","journal-title":"Adv Ther"},{"key":"10.1016\/j.jid.2026.01.016_bib10","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26000655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X26000655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T20:07:56Z","timestamp":1779998876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X26000655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0022202X26000655"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2026.01.016","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Baricitinib in the treatment of adults with pyoderma gangrenosum: An open-label pilot trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2026.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Society for Investigative Dermatology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}